Atlanta Capital Management Co. L L C reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 3.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,511,803 shares of the company’s stock after selling 61,277 shares during the period. Atlanta Capital Management Co. L L C owned approximately 0.31% of Zoetis worth $94,307,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of the company. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Zoetis by 51.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 31,041 shares of the company’s stock worth $1,936,000 after buying an additional 10,539 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Zoetis in the second quarter worth about $917,000. Moors & Cabot Inc. lifted its stake in shares of Zoetis by 1.1% in the second quarter. Moors & Cabot Inc. now owns 14,969 shares of the company’s stock worth $929,000 after buying an additional 170 shares in the last quarter. Green Square Capital LLC lifted its stake in shares of Zoetis by 3.0% in the second quarter. Green Square Capital LLC now owns 10,571 shares of the company’s stock worth $659,000 after buying an additional 308 shares in the last quarter. Finally, Dana Investment Advisors Inc. lifted its stake in shares of Zoetis by 41.4% in the second quarter. Dana Investment Advisors Inc. now owns 82,091 shares of the company’s stock worth $5,121,000 after buying an additional 24,041 shares in the last quarter. 93.20% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Zoetis Inc. (NYSE:ZTS) traded down 0.0640% on Tuesday, hitting $63.6892. 289,982 shares of the company were exchanged. The company has a 50-day moving average price of $63.50 and a 200 day moving average price of $60.66. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $65.83. The firm has a market cap of $31.15 billion, a P/E ratio of 36.0029 and a beta of 1.02.
Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.53. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 EPS. Analysts predict that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be given a dividend of $0.105 per share. This represents a $0.42 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio (DPR) is presently 23.73%.
ZTS has been the topic of several research reports. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Hilliard Lyons initiated coverage on shares of Zoetis in a research report on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective for the company. Deutsche Bank AG restated a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Zoetis in a research report on Monday, July 17th. Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research report on Friday, July 21st. Finally, Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $65.44.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.